Vectored delivery of the ZMapp antibody cocktail (c2G4, c4G7, and c13C6) by 
using recombinant adeno-associated viruses (rAAVs) could be useful for 
preventive immunization against Ebola virus infections because rAAVs can 
generate long-term antibody expression. Three rAAVs (serotype 9) encoding 
chimeric ZMapp antibodies were produced by triple-plasmid transfection up to 
10 L-scale in WAVE bioreactors using HEK293 cells grown in suspension/serum-free 
conditions. Efficacy of AAV-c2G4 via intravenous (i.v.), intramuscular (i.m.), 
and intranasal (i.n.) routes of administration was evaluated in mice with two 
different doses of 2.7 × 1010 and 13.0 × 1010 vector genomes (vg). The best 
protective efficacies after Ebola challenge were obtained with the i.v. and i.m. 
routes. Serum concentrations of ZMapp antibodies positively correlated with 
survivability. Efficacy of the rAAV-ZMapp cocktail was then evaluated at a 
higher dose of 30.0 × 1010 vg. It conferred a more robust protection (90% i.v. 
and 60% i.m.) than rAAV-c4G7 (30%) and rAAV-c13C6 (70%), both administered 
separately at the same dose. Delivery of rAAV-c2G4 alone achieved up to 100% 
protection (100% i.v. and 90% i.m.) at the same dose. In conclusion, the 
preventive treatment was effective in mice. However, no advantage was observed 
for using the rAAV-ZMapp cocktail in comparison to the utilization of the single 
rAAV-c2G4.